AGIOS PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
AGIOS PHARMACEUTICALS, INC. (AGIO) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2023-02-23
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2022-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2022-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $64.00K.
- 2022-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $95.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-23 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $64.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $95.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $183.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $300.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $871.00K 10-Q · filed 2021-07-29 |
| 2021-03-31 | $502.00K 10-Q · filed 2021-04-29 |
| 2020-12-31 | $590.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $677.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $793.00K 10-Q · filed 2020-07-30 |
| 2020-03-31 | $881.00K 10-Q · filed 2020-04-30 |
| 2019-12-31 | $993.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |